DLBCL and Extranodal Disease

A re-evaluation of the clinical significance of extranodal disease among patients with diffuse large B-cell lymphoma (DLBCL) who were staged with positron emission tomography/computed tomography was undertaken to determine the prognostic impact of extranodal disease.

 

Results were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 444) from Denmark and Canada were included in this retrospective study. Extranodal disease was diagnosed in 286 (64%) patients. Patients with one or two extranodal sites of involvement had a similar outcome: three-year progression-free survival was 68% versus 70%; patients with involvement of more than three extranodal sites had progressed.

Click here for the full article.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.